Sergio Quezada
Founder at ACHILLES THERAPEUTICS PLC
Net worth: 288 901 $ as of 2024-04-29
Sergio Quezada active positions
| Companies | Position | Start | End |
|---|---|---|---|
| ACHILLES THERAPEUTICS PLC | Chief Tech/Sci/R&D Officer | 2020-10-31 | - |
| Founder | 2020-10-31 | - | |
| University College London | Corporate Officer/Principal | 2010-12-31 | - |
Career history of Sergio Quezada
Former positions of Sergio Quezada
| Companies | Position | Start | End |
|---|---|---|---|
Achilles Therapeutics UK Ltd.
 Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | Founder | 2016-04-30 | - |
Training of Sergio Quezada
| Dartmouth Medical School | Doctorate Degree |
| Pontificia Universidad Católica de Chile | Undergraduate Degree |
Statistics
International
| United Kingdom | 4 |
| United States | 2 |
| Chile | 2 |
Operational
| Founder | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Corporate Officer/Principal | 1 |
Sectoral
| Consumer Services | 4 |
| Health Technology | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
 | Health Technology |
| ACHILLES THERAPEUTICS PLC | Health Technology |
- Stock Market
- Insiders
- Sergio Quezada
- Experience
